Catalent signs on to produce Aurinia's newly approved lupus nephritis drug

Just weeks after Aurinia Pharmaceuticals bagged its first FDA green light, the company is turning to one of its clinical manufacturing partners to help bring its drug to market.

Aurinia enlisted Catalent to deliver commercial supply of its oral lupus nephritis drug Lupkynis (voclosporin), the CDMO said Thursday. The multiyear pact follows Lupkynis' January green light and the companies' successful team-up in the clinic.